The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1202
Natalizumab (Tysabri) for Relapsing Multiple Sclerosis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Natalizumab, a recombinant humanized monoclonal antibody, has received accelerated approval from the FDA for intravenous treatment of relapsing forms of multiple sclerosis (MS). The beta interferons and glatiramer acetate are widely used for treatment of MS; they generally reduce the number of relapses by about 30% compared to placebo, and have been shown to be safe and effective for periods ranging from 4 to 10 years.1,2

MECHANISM OF ACTION — Natalizumab is produced in murine myeloma cells. It binds to the α4-subunit of the cell surface adhesion molecule α4ß1 integrin that is expressed on activated lymphocytes and monocytes; this blocks cell adhesion and prevents leukocyte migration across the blood-brain barrier, which may interrupt the inflammatory cascade in MS. In animal models of MS, the drug reduced leukocyte migration into brain parenchyma ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Natalizumab (Tysabri) for Relapsing Multiple Sclerosis
Article code: 1202a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian